

CONFIDENTIAL

Limited Use Label License: Research Use Only Codex® HiCap RNA Polymerase Product

BEFORE PLACING AN ORDER OR USING ANY LICENSED PRODUCTS, PLEASE READ THE TERMS AND CONDITIONS SET FORTH IN THIS LULL.

BY USE OF THIS PRODUCT, RECIPIENT AGREES TO BE BOUND BY THE TERMS AND CONDITIONS OF THIS LIMITED USE STATEMENT. THESE TERMS AND CONDITIONS ARE APPLICABLE AS OF THE FIRST DATE ON WHICH YOU PURCHASE OR USE THIS LICENSED PRODUCT.

This Limited Use Label License (“LULL”), which supersedes and voids all previous versions, applies to all research use only Codex® HiCap RNA Polymerase Product (each, a “Licensed Product”) sold to you by Aldevron under license from Codexis, Inc. (“Codexis”). Subject to the terms and conditions set forth in this LULL, the recipient of any Licensed Product from Aldevron is granted a limited, non-exclusive, and non-transferable right to use the Licensed Product and Enabled Product for Research and Development Use but not for any Excluded Use, as such terms are defined herein. The use of any Licensed Product for a Commercial Purpose is strictly forbidden. In the event of any conflict between the terms of this LULL and Aldevron’s standard terms and conditions, the terms of this LULL shall govern.

1. The following definitions apply to this LULL:

“Research and Development Use” means the use of the Licensed Product or Enabled Products in basic research, drug discovery, drug development, pre-clinical, and clinical activities for the development of therapeutic, prophylactic or diagnostic applications for human or veterinary uses (e.g., toxicology and tolerability, biodistribution, and translational studies), including activities needed to seek any regulatory approval (excluding, for clarity, the filing of an application for regulatory approval to market a drug or biologic or other approvals required for Commercial Use). By way of non-limiting example, Research and Development Use includes pre-clinical studies, clinical studies, efficacy studies, formulation development and optimization, and regulatory affairs and manufacturing activities in support of the foregoing. Research and Development Use expressly excludes any Excluded Use.

“Commercial Use” means any and all uses of this Licensed Product and Enabled Products by a party for money or other consideration and may include but is not limited to: (a) any use, directly or indirectly, in manufacturing (including use in manufacturing a commercial product), production, production of biomolecules, or quality control; (b) any use to provide a service, information, or data; (c) any use for therapeutic, diagnostic or prophylactic purposes; (d) any sale, resale, leasing or licensing of the Licensed Product or Enabled Product, whether or not for research purposes; or (e) any use of Licensed Product or Enabled Products for commercialization purposes (including by way of non-limiting example, the filing of an application for regulatory approval to market a drug or biologic, any activities necessary to maintain regulatory approval to market a drug or biologic, the seeking of any pricing approval or any other use of the Licensed Product or Enabled Products in the commercialization of any commercial human, microbial, mammalian, veterinary or agricultural application).

“Excluded Use” means (a) any Commercial Use or (b) any use in a manner that is prohibited by applicable laws, rules, and regulations.

“Enabled Product” means any product, that is not the Licensed Product, which is or incorporates a nucleic acid or other biological material created by you or an affiliate through the use of the Licensed Product.

Effective June 21, 2024

CONFIDENTIAL

“Patent Rights” means (a) any patents and patent applications listed on Appendix A, (b) any substitutions, divisions, continuations, reissues, renewals, re-examinations or extensions thereof, and (c) any foreign or international equivalents of any of the foregoing.

2. You may not, under any circumstances:
 - a. Use any Licensed Product or Enabled Product for any Excluded Use;
 - b. Use or transfer any Licensed Product for any Commercial Use including, without limitation, use as a component in a commercial product or for manufacture of a commercial product or commercial drug product; or
 - c. Attempt to characterize the Licensed Product, or make, have made, reverse engineer, develop, disassemble, manipulate, replicate, copy or manufacture the Licensed Product or otherwise perform analyses directed or intended at learning the methodology, components, formulae, sequence, processes or other information pertaining to the make-up or production of the Licensed Product other than when and to the extent that it is necessary for the Purpose, unless with the prior express authorization in writing by Aldevron and Codexis.
 - d. Transfer, sell, release, convey, distribute, or otherwise provide access to the Licensed Product to any third party or affiliate without first obtaining the prior written consent of Aldevron, which may be withheld at Aldevron’s sole discretion.
3. If you are interested in obtaining the right to use the Licensed Product or Enabled Products for any Commercial Use or development activities not expressly permitted under this LULL, or if you have questions regarding the same, please contact an Aldevron licensing representative by email at contracts@aldevron.com.
4. You may use only the amount of the Licensed Product purchased from Aldevron, and you may not manufacture any further quantities of Licensed Product, whether for internal or other use or for a third party.
5. Except for the limited rights expressly granted under this LULL with respect to each Licensed Product, no other rights are transferred or granted to you. The Licensed Product and its use are the subject of one or more Patent Rights owned by Codexis (see Appendix A) and the purchase of the Licensed Product does not convey a license to you under any claims in the foregoing Patent Rights directed to the Licensed Product or the use, development or commercialization thereof, except as expressly set forth in this LULL.
6. You will indemnify, defend and hold harmless Aldevron, its affiliates, and its directors, officers, employees, agents, successors and assigns from and against any liability, damage, loss or expense (including reasonable attorneys’ fees and expenses) arising out of or related to the exercise of any rights granted to you under this LULL or any breach of this LULL by you ; *provided*, that to the extent the foregoing is not permitted by law, you agree that you, and not Aldevron, shall be responsible for any liability, damage, loss or expense arising out of or related to the exercise of any rights granted to you under this LULL or any breach of this LULL by you .
7. EXCEPT TO THE EXTENT EXPRESSLY PROVIDED HEREIN, THE PRODUCTS AND ALDEVRON’S SERVICES ARE PROVIDED TO CLIENT "AS IS" WITHOUT ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED AND WITHOUT ANY REPRESENTATION OR WARRANTY THAT THE PRODUCTS AND THE USE OF THE PRODUCTS WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER RIGHT OF ANY PARTY. IN ADDITION, ALDEVRON HEREBY EXPRESSLY DISCLAIMS ANY WARRANTY REGARDING RESULTS OBTAINED THROUGH THE USE

Effective June 21, 2024

CONFIDENTIAL

OF THE LICENSED PRODUCTS OR ENABLED PRODUCTS, INCLUDING WITHOUT LIMITATION ANY CLAIM OF INACCURATE, INVALID, OR INCOMPLETE RESULTS.

8. TO THE MAXIMUM EXTENT PERMITTED BY LAW, IN NO EVENT SHALL ALDEVRON AND ITS AFFILIATES BE LIABLE TO YOU OR A THIRD PARTY, INCLUDING WITHOUT LIMITATION ANY LOST DIRECT OR INDIRECT PROFITS, SPECIAL, INCIDENTAL, EXEMPLARY, PUNITIVE, OR CONSEQUENTIAL DAMAGES, ARISING FROM OR IN CONNECTION WITH THIS LULL OR YOUR USE OF THE LICENSED PRODUCTS OR ENABLED PRODUCTS, HOWEVER CAUSED, WHETHER BASED ON CONTRACT, TORT, WARRANTY OR OTHER LEGAL THEORY, AND WHETHER OR NOT ALDEVRON OR ITS AFFILIATES HAVE BEEN INFORMED OF THE POSSIBILITY OF SUCH DAMAGES OR IF SUCH DAMAGES WERE REASONABLY FORESEEABLE.
9. This LULL and your right to use the Licensed Products and Enabled Products hereunder shall terminate immediately if you fail to comply with the terms and conditions of this LULL.
10. If Aldevron's license with Codexis for the Licensed Products is terminated, and, at the time such license is terminated you are compliant with the terms and conditions of this LULL, then Codexis shall automatically become the direct licensor of the Licensed Products in substitution of Aldevron under this LULL.
11. Upon termination of this LULL, you shall, destroy all Licensed Products, all Enabled Products, and all components and derivatives thereof in your custody or control, and you shall immediately notify Aldevron of such destruction in writing.

Effective June 21, 2024

CONFIDENTIAL**Appendix A
Patent Rights**

Patent Number	Country Name	Application Number	Filing Date	Publication Number	Publication Date	Issue Date	Status	Title
	Australia	2018292104	26-Nov-2019				Pending	T7 RNA POLYMERASE VARIANTS
	Canada	3066767	09-Dec-2019	3066767	03-Jan-2019		Pending	T7 RNA POLYMERASE VARIANTS
	China (People's Republic)	2018800564119	28-Feb-2020	111417724	14-Jul-2020		Pending	T7 RNA POLYMERASE VARIANTS
	European Patent Convention	18824479.2	17-Dec-2019	3645712	06-May-2020		Pending	T7 RNA POLYMERASE VARIANTS
	Israel	271547	18-Dec-2019				Pending	T7 RNA POLYMERASE VARIANTS
	India	202047003002	23-Jan-2020	202047003002	31-Jan-2020		Pending	T7 RNA POLYMERASE VARIANTS
	New Zealand	759581	26-Nov-2019				Pending	T7 RNA POLYMERASE VARIANTS
11201911346Q	Singapore	11201911346Q	28-Nov-2019			23-Mar-2022	Granted	T7 RNA POLYMERASE VARIANTS
	United States of America	17/558454	21-Dec-2021	20220186197	16-Jun-2022		Pending	T7 RNA POLYMERASE VARIANTS
11,236,312	United States of America	16/942599	29-Jul-2020	20200354699	12-Nov-2020	01-Feb-2022	Granted	T7 RNA POLYMERASE VARIANTS
11,236,311	United States of America	16/938793	24-Jul-2020	20200354698	12-Nov-2020	01-Feb-2022	Granted	T7 RNA POLYMERASE VARIANTS
10,738,286	United States of America	16/012462	19-Jun-2018	20190002850	03-Jan-2019	11-Aug-2020	Granted	T7 RNA POLYMERASE VARIANTS

Effective June 21, 2024

CONFIDENTIAL

	Australia	2018292105	26-Nov-2019				Pending	T7 RNA POLYMERASE VARIANTS
	Canada	3066642	06-Dec-2019	3066642	03-Jan-2019		Pending	T7 RNA POLYMERASE VARIANTS
	China (People's Republic)	2018800562749	28-Feb-2020	111032863	17-Apr-2020		Pending	T7 RNA POLYMERASE VARIANTS
	European Patent Convention	18824385.1	06-Dec-2019	3645711	06-May-2020		Pending	T7 RNA POLYMERASE VARIANTS
	Israel	271553	18-Dec-2019				Pending	T7 RNA POLYMERASE VARIANTS
	Japan	2023-141005	31-Aug-2023	2023-159437	31-Oct-2023		Pending	T7 RNA POLYMERASE VARIANTS
	Japan	2019-571591	25-Dec-2019	2020-530266	22-Oct-2020		Pending	T7 RNA POLYMERASE VARIANTS
	Korea, Republic of	10-2020-7002946	30-Jan-2020	10-2020-0023455	04-Mar-2020		Pending	T7 RNA POLYMERASE VARIANTS
	New Zealand	759580	26-Nov-2019				Pending	T7 RNA POLYMERASE VARIANTS
2796061	Russian Federation	2020103726	29-Jan-2020	2020103726	30-Jul-2021	16-May-2023	Granted	T7 RNA POLYMERASE VARIANTS
	Singapore	10202114203X	21-Dec-2021				Pending	T7 RNA POLYMERASE VARIANTS
10,793,841	United States of America	16/012478	19-Jun-2018	20190002851	03-Jan-2019	06-Oct-2020	Granted	T7 RNA POLYMERASE VARIANTS

Effective June 21, 2024